nach oben

Drug Safety

Erschienen in:

01.08.2003 | Review Article

Drug Interactions with Angiotensin Receptor Blockers: A Comparison with Other Antihypertensives

verfasst von: Dr Thomas Unger, Elena Kaschina

Erschienen in: Drug Safety | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

The ever-increasing introduction of new therapeutic agents means that the potential for drug interactions is likely to escalate. Numerous different classes of drugs are currently used to treat hypertension. The angiotensin receptor blockers offer one of the newest approaches to the management of patients with high blood pressure. Compared with other classes of antihypertensive agents, the angiotensin receptor blockers appear overall to have a low potential for drug interactions, but variations within the class have been detected. Losartan and irbesartan have a greater affinity for cytochrome P450 (CYP) isoenzymes and, thus, are more likely to be implicated in drug interactions. There is pharmacokinetic evidence to suggest that such interactions could have a clinical impact. Candesartan cilexetil, valsartan and eprosartan have variable but generally modest affinity and telmisartan has no affinity for any of the CYP isoenzymes. In vitro studies and pharmacokinetic/pharmacodynamic evaluation can provide evidence for some interactions, but only a relatively small number of drug combinations are usually studied in this way. The absence of any pharmacokinetic evidence of drug interaction, however, should not lead to complacency. Patients should be made aware of possible interactions, especially involving the concurrent use of over-the-counter products, and it may be prudent for all patients receiving antihypertensive treatment to be monitored for possible drug interactions at their regular check-ups. The physician can help by prescribing agents with a low potential for interaction, such as angiotensin receptor blockers.

Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–21PubMedCrossRef

Materson BJ, Reda DJ, Cushman WC, et al. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hypertens 1995; 8: 189–92PubMedCrossRef

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–71PubMedCrossRef

Nichol MB, Margolies JE, Gill MA. Factors associated with antihypertensive prescribing. Ann Pharmacother 1997; 31: 154–9PubMed

Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12: 485–94PubMedCrossRef

Kurfees JF, Dotson RL. Drug interactions in the elderly. J Fam Pract 1987; 25: 477–88PubMed

Stewart RB, Cooper JW. Polypharmacy in the aged: practical solutions. Drugs Aging 1994; 4: 449–61PubMedCrossRef

Barnett NL, Denham MJ, Francis SA. Over-the-counter medicines and the elderly. J R Coll Physicians Lond 2000; 34: 445–6PubMed

Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol 2000; 56: 501–9PubMedCrossRef

10.

Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19: 359–89PubMedCrossRef

11.

Jaski ME, Schwartzberg JG, Guttman RA, et al. Medication review and documentation in physician office practice. Eff Clin Pract 2000; 3: 31–4PubMed

12.

Shintani S, Murase H, Tsukagoshi H, et al. Glycyrrhizin (licorice)-induced hypokalemic myopathy: report of two cases and review of the literature. Eur Neurol 1992; 32: 44–51PubMedCrossRef

13.

Brinker F. Herb contraindications and drug interactions. Sandy (OR): Eclectic Institute, 1997

14.

Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker: telmisartan. Blood Press 2001; 10Suppl. 1: 27–32CrossRef

15.

Elliott WJ. Circadian variation in blood pressure: implications for the elderly patient. Am J Hypertens 1999; 12(2 Pt 2): 43S–9SPubMedCrossRef

16.

Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83

17.

Diokno AC, Brown MB, Herzog AR. Relationship between use of diuretics and continence status in the elderly. Urology 1991; 38: 39–42PubMedCrossRef

18.

Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188–91PubMedCrossRef

19.

Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996; 15: 91–106PubMedCrossRef

20.

Saruta T, Arakawa K, Iimura O, et al. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999; 22: 197–202PubMedCrossRef

21.

Gennari FJ, Gennari AS. Recent advances in the management of hypertension in the elderly. Curr Hypertens Rep 2000; 2: 543–50PubMedCrossRef

22.

Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000; 17: 441–52PubMedCrossRef

23.

Krishnan KR. Depression as a contributing factor in cerebrovascular disease. Am Heart J 2000; 140(4 Suppl.): 70–6PubMedCrossRef

24.

Lindeman RD. Should the sale of analgesic mixtures and nonsteroidal anti-inflammatory agents (NSAIDs) continue to be allowed as over-the-counter (OTC) medications? Geriatr Nephrol Urol 1999; 9: 3–4PubMedCrossRef

25.

Hayreh SS, Zimmerman MB, Podhajsky P, et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994; 117: 603–24PubMed

26.

Imai Y, Tsuji I, Nagai K, et al. Circadian blood pressure variation related to morbidity and mortality from cerebrovascular and cardiovascular diseases. Ann N Y Acad Sci 1996; 15: 172–85CrossRef

27.

Watanabe N, Imai Y, Nagai K, et al. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke 1996; 27: 1319–27PubMedCrossRef

28.

Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619–24PubMed

29.

Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56: 135–40PubMedCrossRef

30.

Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000; 20: 130–9PubMedCrossRef

31.

Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445–9PubMedCrossRef

32.

Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62: 417–25PubMedCrossRef

33.

Goldberg MR, Lo MW, Deutsch PJ, et al. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996; 59: 268–74PubMedCrossRef

34.

Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40: 263–81PubMedCrossRef

35.

Williamson KM, Patterson JH, McQueen RH, et al. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998; 63: 316–23PubMedCrossRef

36.

Chawla PS, Kochar MS. Effect of pain and nonsteroidal analgesics on blood pressure. Wis Med J 1999; 98: 22–9

37.

Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000; 36: 461–5PubMedCrossRef

38.

Nawarskas JJ, Townsend RR, Cirigliano MD, et al. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999; 12: 784–9PubMedCrossRef

39.

Goldberg MR, Lo MW, Bradstreet TE, et al. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 1995; 49: 115–9PubMedCrossRef

40.

Kong AN, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995; 35: 1008–15PubMed

41.

Schaefer KL, Porter JA. Angiotensin II receptor antagonists: the prototype losartan. Ann Pharmacother 1996; 30: 625–36PubMed

42.

Lill J, Bauer LA, Horn JR, et al. Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm 2000; 57: 1579–84PubMed

43.

Zaidenstein R, Soback S, Gips M, et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 2001; 23: 369–73PubMedCrossRef

44.

Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403–7PubMedCrossRef

45.

Bonate PL, Reith K, Weir S. Drug interactions at the renal level: implications for drug development. Clin Pharmacokinet 1998; 34: 375–404PubMedCrossRef

46.

Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J Rheumatol 2000; 27: 2232–6PubMed

47.

McCrea JB, Lo MW, Tomasko L, et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol 1995; 35: 1200–6PubMed

48.

Ruilope LM, Simpson RL, Toh J, et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5: 32–40PubMedCrossRef

49.

Waldmeier F, Flesch G, Müller P, et al. Pharmacokinetics, disposition and biotransformation of [¹⁴C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997; 27: 59–71PubMedCrossRef

50.

Colussi DM, Parisot C, Rossolino ML, et al. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 1997; 37: 214–21PubMed

51.

Leung M, Remick RA. Potential drug interaction between lithium and valsartan. J Clin Psychopharmacol 2000; 20: 392–3PubMedCrossRef

52.

Bindschedler M, Degen P, Flesch G, et al. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997; 52: 371–8PubMedCrossRef

53.

Diovan® tablets prescribing information. Novartis Pharmaceuticals Corporation, East Hanover (NJ), 2002

54.

Schmidt EK, Antonin KH, Flesch G, et al. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol 1998; 53: 451–8PubMedCrossRef

55.

Sifton DW, editor. Physicians Desk reference. Montvale (NJ): Medical Economics Co Inc., 2000

56.

Mallion JM, Baguet JP, Siche JP, et al. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens 1998; 16Suppl. 1: S75–S9

57.

McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998; 56: 847–69PubMedCrossRef

58.

Jonkman JHG, van Lier JJ, van Heiningen PNM, et al. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens 1997; 11Suppl. 2: S31–S5PubMed

59.

Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418–26PubMedCrossRef

60.

See S, Stirling AL. Candesartan cilexetil: an angiotensin IIreceptor blocker. Am J Health Syst Pharm 2000; 57: 739–46PubMed

61.

Bourrie M, Meunier V, Berger Y, et al. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27: 288–96PubMed

62.

Mangold B, Gielsdorf W, Marino MR. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin. Eur J Clin Pharmacol 1999; 55: 593–8PubMedCrossRef

63.

Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin Pharmacokinet 2001; 40: 605–14PubMedCrossRef

64.

Marino MR, Vachharajani NN, Hadjilambris OW. Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J Clin Pharmacol 2000; 40: 875–9PubMedCrossRef

65.

Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy 1999; 19(4 Pt 2): 73S–8SPubMedCrossRef

66.

Blum RA, Kazierad DJ, Tenero DM. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy 1999; 19(4 Pt 2): 79S–85SPubMedCrossRef

67.

Kazierad DJ, Martin DE, Ilson B, et al. Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol 1998; 38: 649–53PubMed

68.

Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127–56CrossRef

69.

Stangier J, Su CAPF. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1338–46PubMed

70.

Yong C-L, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000; 40: 1323–30

71.

Stangier J, Su CA, Fraunhofer A, et al. Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1338–46PubMed

72.

Stangier J, Su CAPF, Stähle H, et al. Pharmacokinetic evidence of lack of interaction between telmisartan and simvastatin [abstract PC23]. J Renin Angiotensin Aldosterone Syst 2001; 2: 63

73.

Stangier J, Hendriks MGC, van Lier JJ, et al. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1331–7PubMed

74.

Heuer HJ, Dilger C, Michael, et al. Influence of repeated oral doses of telmisartan on the clinical pharmacology of glibenclamide in healthy subjects [abstract no. 38]. Eur J Clin Pharmacol 1998; 54: A12

75.

McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833–50PubMedCrossRef

76.

McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001; 24: 66–72PubMedCrossRef

77.

Stangier J, Su CAPF, Hendriks MGC, et al. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol 2000; 40: 1373–9PubMed

78.

Dunselman PHJM, the Replacement of Angiotensin Converting Enzyme Inhibition (REPLACE) Investigators. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. Int J Cardiol 2001; 77: 131–8

79.

Boehringer Ingelheim Pharma Inc. (Data on file)

80.

Greenberg A. Diuretic complications. Am J Med Sci 2000; 319(1): 10–24PubMedCrossRef

81.

Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998; 18: 83–97PubMedCrossRef

82.

Ambrosioni E, Borghi C, Costa FV. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol 1987; 23Suppl. 1: 43S–50SPubMedCrossRef

83.

Nurnberger JJ. Diuretic-induced lithium toxicity presenting as mania. J Nerv Ment Dis 1985; 173: 316–8PubMedCrossRef

84.

Steiness E, Waldorff S. Different interactions of indomethacin and sulindac with thiazides in hypertension. Br Med J (Clin Res Ed) 1982; 285: 1702–3CrossRef

85.

Facino RM, Lanzani R. Interaction of a series of beta-adrenergic blocking drugs with rat hepatic microsomal monooxygenase. Pharmacol Res Commun 1979; 11: 433–45PubMedCrossRef

86.

Ferrari S, Leemann T, Dayer P. The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro. Life Sci 1991; 48: 2259–65PubMedCrossRef

87.

Lucas H. Drug interactions that matter: (5) Antihypertensives. Pharm J 1999; 262: 547–51

88.

Markowitz JS, Wells BG, Carson WH. Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 1995; 29: 603–9PubMed

89.

Westphal K, Weinbrenner A, Giessmann T, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000; 68: 6–12PubMedCrossRef

90.

De Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 1990; 29: 486–90PubMedCrossRef

91.

Majumdar SR. Beta-blockers for the treatment of hypertension in patients with diabetes: exploring the contraindication myth. Cardiovasc Drugs Ther 1999; 13: 435–9PubMedCrossRef

92.

Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57PubMedCrossRef

93.

Kjeldsen SE, Syvertsen JO, Hedner T. Cardiac conduction with diltiazem and beta-blockade combined: a review and report on cases. Blood Press 1996; 5: 260–3PubMedCrossRef

94.

Opie LH. Calcium channel antagonists: part IV: side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther 1988; 2: 177–89PubMedCrossRef

95.

Rosenthal T, Ezra D. Calcium antagonists: drug interactions of clinical significance. Drug Saf 1995; 13: 157–87PubMedCrossRef

96.

Doering W. Effect of coadministration of verapamil and quinidine on serum digoxin concentration. Eur J Clin Pharmacol 1983; 25: 517–21PubMedCrossRef

97.

Lessem J, Bellinetto A. Interaction between digoxin and the calcium antagonists nicardipine and tiapamil. Clin Ther 1983; 5: 595–602PubMed

98.

Paolisso G, Gambardella A, Verza M, et al. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6: 175–9PubMed

99.

Ahmad S. Drug interaction induces hypoglycemia. J Fam Pract 1995; 40: 540–1PubMed

100.

Veyre B, Ginon I, Vial T, et al. Hypoglycemia caused by interference between an angiotensin-converting enzyme inhibitor and a hypoglycemic sulfonamide. Presse Med 1993; 22: 738PubMed

101.

Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet 1990; 18: 210–9PubMedCrossRef

102.

Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993; 25: 20–58PubMedCrossRef

103.

Breckenridge AM. Drug interactions with ACE inhibitors. J Hum Hypertens 1989; 3Suppl. 1: 133–8PubMed

104.

Mazurek W, Haczynski J. Interaction of captopril and digoxin. Pol Tyg Lek 1993; 48: 834–5PubMed

105.

Finley PR, O’Brien JG, Coleman RW. Lithium and angiotensinconverting enzyme inhibitors: evaluation of a potential interaction. J Clin Psychopharmacol 1996; 16: 68–71PubMedCrossRef

106.

Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36: 425–38PubMedCrossRef

107.

Johnson MD, Newkirk G, White Jr JR. Clinically significant drug interactions. Postgrad Med 1999; 105: 193–5, 200, 205-6PubMed

108.

Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82PubMedCrossRef

109.

Snawder JE, Lipscomb JC. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul Toxicol Pharmacol 2000; 32: 200–9PubMedCrossRef

110.

Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes. Int J Mol Med 1999; 3: 227–38PubMed

Titel: Drug Interactions with Angiotensin Receptor Blockers: A Comparison with Other Antihypertensives
verfasst von: Dr Thomas Unger
Elena Kaschina
Publikationsdatum: 01.08.2003
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 10/2003
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200326100-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2003

Stimulating Spontaneous Reporting of Adverse Drug Reactions by a Patient: Directed Incentive

Drug Adverse Reaction Target Database (DART)

Do Antiepileptic Drugs Play a Role in Sudden Unexpected Death in Epilepsy?

Assessing the Impact of Drug Safety Signals from the WHO Database Presented in ‘SIGNAL’

Drug-Induced Myelosuppression

Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults